Home/Pipeline/Mini-CAR for SLE

Mini-CAR for SLE

Systemic Lupus Erythematosus (SLE)

Pre-clinicalActive

Key Facts

Indication

Systemic Lupus Erythematosus (SLE)

Phase

Pre-clinical

Status

Active

Company

Caravan Biologix

About Caravan Biologix

Caravan Biologix is pioneering an AI-designed, cell-free CAR therapeutic platform using engineered biospheres derived from allogeneic cells. Its core technology, Mini-CAR, is designed to offer superior tumor penetration, reduced toxicity like cytokine release syndrome (CRS), and simplified manufacturing compared to whole-cell therapies. The company's strategy involves building an internal pipeline while actively seeking platform licensing partnerships to develop therapies for oncology and hereditary diseases.

View full company profile

Therapeutic Areas

Oncology Hereditary Disease Autoimmune Disease

Other Systemic Lupus Erythematosus (SLE) Drugs

Drug	Company	Phase	Status
hCDR1 (Edratide)	XTL Biopharmaceuticals	Phase 2	Completed
Nipocalimab	johnson-and-johnson-innovative-medicine	Phase 3	Active (Fast Track Designation)
EYD-001 (Takinib analog)	EydisBio	Preclinical	Potential indication
IFNα Kinoid (IFN-K)	Neovacs	Phase IIb	Inactive / On Hold
Brepocitinib (PF-06700841)	Priovant Therapeutics	Phase 3	Active
aiSLE® DX Flare Risk Index	Progentec Diagnostics	Commercial	Active
aiSLE® DX Disease Activity Index	Progentec Diagnostics	Commercial	Active
OASIS Study (Digital Biomarkers)	Progentec Diagnostics	Clinical Study	Active
RSLV-132	Resolve Therapeutics	Phase 2	Completed
Internal Program	BenevolentAI	Preclinical	Active
Telitacicept (RC18)	RemeGen	Approved	Marketed
Cenerimod	Ono Pharmaceutical	Phase 3	Active